Literature DB >> 9777922

Combination therapy for early Alzheimer's disease: what are we waiting for?

P M Doraiswamy1, D C Steffens.   

Abstract

The practical pharmacological approaches currently available to palliate the cognitive and functional losses in early Alzheimer's disease (AD) include cholinesterase inhibitors (ChEI), antioxidants (e.g., vitamin E), anti-inflammatory agents, estrogen, seligiline, vasoactive agents, and ginkgo biloba. Reviewing available data on these therapies and using models from medical illnesses such as cancer and hypertension, we highlight the urgent need for evaluating combination therapies in early AD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9777922     DOI: 10.1111/j.1532-5415.1998.tb04556.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  5 in total

Review 1.  Positron emission tomography for the early diagnosis of dementia.

Authors:  K Brummel-Smith
Journal:  West J Med       Date:  1999 Nov-Dec

Review 2.  Cholinesterase inhibitors for Alzheimer's disease.

Authors:  J Grutzendler; J C Morris
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Combination therapy in Alzheimer's disease: a review of current evidence.

Authors:  Beate Schmitt; Tanja Bernhardt; Hans-Juergen Moeller; Isabella Heuser; Lutz Frölich
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

4.  Current and future treatments for cognitive deficits in dementia.

Authors:  B M McLendon; G G Chen; P M Doraiswamy
Journal:  Curr Psychiatry Rep       Date:  2000-02       Impact factor: 5.285

5.  Development, Application, and Results from a Precision-medicine Platform that Personalizes Multi-modal Treatment Plans for Mild Alzheimer's Disease and At-risk Individuals.

Authors:  Dorothy Keine; John Q Walker; Brian K Kennedy; Marwan N Sabbagh
Journal:  Curr Aging Sci       Date:  2018
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.